Clinical trials: Tardive Dyskinesia
Tardive Dyskinesia
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily for the treatment of Tardive Dyskinesia (TD)…
- Trial name
- NCT01733121
- Testing
- NBI-98854
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 102 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- KINECT 3 (NCT02274558)
- Testing
- NBI-98854
- Where
- 54 sites in United States, Canada and 1 more
- Volunteers
- 234 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia, Tardive Dystonia
Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
Rationale: Tardive dyskinesia and dystonia (TDD) are severe side effects of dopamine blocking agents, particularly antipsychotics.
- Trial name
- NCT02524886
- Testing
- GPi DBS with Medtronic electorde and Activa PC pulsegenerator
- Where
- Netherlands
- Volunteers
- 1 people
- Sponsor
- GGZ Centraal
Tardive Dyskinesia
The Assessment of Movement Disorders Utilizing Live Two-Way Video
The purpose of this project is to determine the equivalency of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) examinations conducted via live two-way video versus live examinations completed in-person
- Trial name
- NCT01467089
- Testing
- Two way video assessment
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
Tardive Dyskinesia
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on therapy to antipsychotics will be performed to examine the effects of melatonin on tardive dyskinesia symptoms and cognitive deficits in 120…
- Trial name
- NCT01391390
- Testing
- Melatonin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Beijing HuiLongGuan Hospital
Neuroleptic-induced Tardive Dyskinesia
Sarizotan in the Treatment of Neuroleptic-induced Tardive Dyskinesia
TD is a troublesome and potentially irreversible side effect associated with the use of neuroleptics. While the newer neuroleptics are improved in this regard, they all still carry the risk of TD.
- Trial name
- NCT00310661
- Testing
- Sarizotan
- Where
- 2 sites in Canada, India
- Volunteers
- 60 people
- Sponsor
- Centre for Addiction and Mental Health
Tardive Dyskinesia
Levetiracetam Treatment of Tardive Dyskinesia
This is a placebo-controlled study designed to learn if levetiracetam is effective for tardive dyskinesia.
- Trial name
- NCT00291213
- Testing
- levetiracetam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Tardive Dyskinesia
Pyridoxal Kinase Activity in Tardive Dyskinesia
Objectives: The mechanisms of tardive dyskinesia (TD) remain unclear, although pathophysiologic theories have proposed mechanisms such as dopamine receptor supersensitivity, the degeneration of cholinergic striatal interneurons…
- Trial name
- NCT01908452
- Testing
- Pyridoxine
- Where
- 3 sites in Israel
- Sponsor
- Beersheva Mental Health Center
Dyskinesia, Drug-Induced
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
This study will assess the risk of experiencing tardive dyskinesia and other movement disturbances associated with three atypical antipsychotic drugs among middle-aged and elderly psychiatric patients.
- Trial name
- NCT00255879
- Testing
- Quetiapine, Risperidone, Olanzapine
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
The objective of the study is to determine whether Panax Ginseng with multiple interactions with key components of brain signaling pathway, can augment the effects of antipsychotics in Schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tardive Dyskinesia, Insulin Resistance
- Trial name
- NCT00401089
- Testing
- Panax Ginseng
- Where
- 4 sites in Canada, United Kingdom
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
Randomized, controlled, double-blind, two-armed clinical investigation to show the efficacy and safety of transcutaneous vagus nerve stimulation (t-VNS), applied at the left auricle, in schizophrenia.
- Trial name
- 02VNS2009 (NCT01176721)
- Testing
- t-VNS verum
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- cerbomed GmbH
Tardive Dyskinesia
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and 50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects with schizophrenia or schizoaffective…
- Trial name
- NCT01267188
- Testing
- NBI-98854
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Piracetam for Treatment Tardive Dyskinesia
The mechanism involved in the development of tardive dyskinesia (TD) is complicated. It now seems that several neurotransmitter systems may be affected, including dopaminergic, noradrenergic, gamma-amino-butyric acid (GABA)…
- Trial name
- NCT00190008
- Testing
- piracetam
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Beersheva Mental Health Center
Tardive Dyskinesia, Neurocognitive Function
Tardive Dyskinesia and Cognitive Function
Previous researchers indicate that impaired cognitive flexibility was the primary factor distinguishing patients with from those without tardive dyskinesia (TD)1, and cognitive dysfunction correlates positively with the severity…
- Trial name
- TD (NCT00926965)
- Testing
- amisulpride, Olanzapine, Conventional antipsychotics
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Dystonia, Movement Disorder
Efficacy and Safety of Deep Brain Stimulation (DBS) of the Pallidal (GPi) in Patients With Tardive Dystonia
The purpose of this randomized, double blind, multi-center study is to assess the efficacy and safety of bilateral pallidal deep brain stimulation in patients with tardive dystonia.
- Trial name
- NCT00331669
- Testing
- deep brain stimulation
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Charite University, Berlin, Germany
Dyskinesia, Drug-Induced
Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00837707
- Testing
- aripiprazole
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Tardive Dyskinesia, Schizophrenia
Extract of Ginkgo Biloba and Tardive Dyskinesia
The purpose of this study is to determine whether Extract of Ginkgo Biloba is effective in the treatment on Tardive dyskinesia
- Trial name
- EGBTD (NCT00672373)
- Testing
- Extract of Ginkgo Biloba (EGb-761 capsules)
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Beijing HuiLongGuan Hospital
Neuroleptic-Induced Tardive Dyskinesia
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications.
- Trial name
- NCT00621998
- Testing
- risperidone, olanzapine
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome
The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
A short term post-market monitoring of serum prolactin level change among patients with schizophrenia shifting from other antispychotics to different dosages of aripiprazole.
- Trial name
- NCT00468533
- Testing
- Aripiprazole
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Yu-Li Hospital
Tardive Dyskinesia
Treatment of Tardive Dyskinesia With Galantamine
Tardive dyskinesia (TD), a form of movement disorder, remains a problem for some patients who received antipsychotic medications.
- Trial name
- NCT00164242
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Caroff, Stanley N., M.D.